MCID: GST019
MIFTS: 68

Gastrointestinal Stromal Tumor malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Gastrointestinal Stromal Tumor

About this section
Sources:
65UMLS, 49OMIM, 10Disease Ontology, 11diseasecard, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 45NIH Rare Diseases, 36MeSH, 24GTR, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Gastrointestinal Stromal Tumor:

Name: Gastrointestinal Stromal Tumor 49 10 11 22 23 47 12 51 67
Gist 10 45 22 23 51 67
Gastrointestinal Stromal Sarcoma 45 23 51 65
Gastrointestinal Stromal Tumors 45 36 24 65
Paraganglioma and Gastric Stromal Sarcoma 65
Gastrointestinal Stromal Tumor, Familial 49
 
Gastrointestinal Stromal Tumor, Somatic 49
Stromal Tumor of Gastrointestinal Tract 10
Gastrointestinal Stromal Neoplasm 23
Plexosarcoma 65
Gant 10

Characteristics:

Orphanet epidemiological data:

51
gastrointestinal stromal tumor:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult

HPO:

61
gastrointestinal stromal tumor:
Inheritance: sporadic, autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 606764
Disease Ontology10 DOID:9253
MeSH36 D046152
NCIt42 C3868
Orphanet51 44890
ICD10 via Orphanet28 C26.9
MESH via Orphanet37 D046152
UMLS via Orphanet66 C0238198
MedGen34 C0238198
UMLS65 C0238198, C2931518, C1847319 C3179349, more

Summaries for Gastrointestinal Stromal Tumor

About this section
OMIM:49 Gastrointestinal stromal tumors are mesenchymal tumors found in the gastrointestinal tract that originate from the... (606764) more...

MalaCards based summary: Gastrointestinal Stromal Tumor, also known as gist, is related to paraganglioma and gastric stromal sarcoma and fibrosarcoma, and has symptoms including sarcoma, neoplasm of the stomach and feeding difficulties in infancy. An important gene associated with Gastrointestinal Stromal Tumor is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Cardiac Progenitor Differentiation and C-MYB transcription factor network. Affiliated tissues include endothelial, small intestine and colon, and related mouse phenotypes are tumorigenesis and digestive/alimentary.

NIH Rare Diseases:45 Gastrointestinal stromal tumors are a type of soft tissue sarcoma (tumor) that usually begins in cells in the wall of the stomach, intestines, or rectum. these tumors may be noncancerous or cancerous. they can affect adults, adolescents, or children.  it is estimated that around 5,000 new cases of gastrointestinal stromal tumors are diagnosed in the united states each year. last updated: 4/27/2010

UniProtKB/Swiss-Prot:67 Gastrointestinal stromal tumor: Common mesenchymal neoplasms arising in the gastrointestinal tract, most often in the stomach. They are histologically, immunohistochemically, and genetically different from typical leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are composed of a fairly uniform population of spindle-shaped cells. Some tumors are dominated by epithelioid cells or contain a mixture of spindle and epithelioid morphologies. Primary GISTs in the gastrointestinal tract commonly metastasize in the omentum and mesenteries, often as multiple nodules. However, primary tumors may also occur outside of the gastrointestinal tract, in other intra-abdominal locations, especially in the omentum and mesentery.

Genetics Home Reference:23 A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine. The tumors are thought to grow from specialized cells found in the gastrointestinal tract called interstitial cells of Cajal (ICCs) or precursors to these cells. GISTs are usually found in adults between ages 40 and 70; rarely, children and young adults develop these tumors. The tumors can be cancerous (malignant) or noncancerous (benign).

Wikipedia:68 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the... more...

Related Diseases for Gastrointestinal Stromal Tumor

About this section

Diseases related to Gastrointestinal Stromal Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 786)
idRelated DiseaseScoreTop Affiliating Genes
1paraganglioma and gastric stromal sarcoma32.6SDHA, SDHB, SDHC, SDHD
2fibrosarcoma31.0KIT, PDGFRA, PDGFRB
3vesicoureteral reflux30.7CD34, KIT, KITLG, PDGFRA
4epidermolysis bullosa acquisita30.6ACTC1, KIT, VIM
5rhinitis30.6KIT, PDGFRA
6myelodysplastic syndrome30.3CD34, FLT3, KIT, KITLG, PDGFRB
7hematopoietic stem cell transplantation30.2ABL1, FLT3, KIT, KITLG, PDGFRB
8pheochromocytoma29.8SDHA, SDHB, SDHC, SDHD
9extraneural perineurioma10.7KIT, PDGFRA
10cataract hutterite type10.7SDHB, SDHD
11anus leiomyosarcoma10.7CD34, KIT
12severe canavan disease10.6PDGFRA, PDGFRB
13gallbladder adenoma10.6SDHB, SDHD
14simple partial epilepsy10.6CD34, KIT
15submandibular gland cancer10.6ANO1, CD34, KIT
16multiple chemical sensitivity10.6KIT, KITLG, PDGFRA
17small intestinal sarcoma10.6ANO1, CD34, KIT
18cutaneous leiomyosarcoma10.6ANO1, CD34, KIT
19mast cell neoplasm10.6KIT, KITLG, PDGFRA
20ovary rhabdomyosarcoma10.6CD34, KIT
21indolent systemic mastocytosis10.6CD34, KIT
22pediatric fibrosarcoma10.6CD34, KIT, PDGFRA
23cataract 4, multiple types10.6SDHB, SDHD
24bone angioendothelial sarcoma10.6CD34, KIT, PDGFRA
25total anomalous pulmonary venous return10.6KIT, KITLG, PDGFRA
26exencephaly10.6KIT, KITLG
27conventional angiosarcoma10.6CD34, KIT
28waardenburg's syndrome10.6KIT, KITLG, NTRK3
29diffuse cutaneous mastocytosis10.6KIT, KITLG, NTRK3
30aggressive systemic mastocytosis10.6KIT, PDGFRA
31acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor10.5FLT3, KIT
32breast cancer10.5
33acute myeloid leukemia, kit-related10.5FLT3, KIT
34cutaneous solitary mastocytoma10.5CD34, KIT
35comedo carcinoma10.5KIT, PDGFRA, VIM
36mastocytosis cutaneous with short stature conductive hearing loss and microtia10.5KIT, KITLG, NTRK3, PDGFRA
37acute myeloblastic leukemia without maturation10.5FLT3, KIT
38chronic eosinophilic pneumonia10.5CD34, KIT, KITLG, PDGFRA
39atypical neurofibroma10.5ABL1, CD34, PDGFRB
40tenosynovitis of foot and ankle10.5CD34, KIT, PDGFRA
41cellular schwannoma10.5KIT, PDGFRA, VIM
42systemic scleroderma10.5KIT, KITLG, PDGFRA, PDGFRB
43pancreatitis10.5
44middle ear disease10.5CD34, VIM
45basal ganglia calcification, idiopathic, 510.5CD34, KIT, PDGFRA, PDGFRB
46angiokeratoma of mibelli10.5KIT, PDGFRA, VIM
47desmoplastic infantile astrocytoma10.5ACTC1, KIT, PDGFRA, PDGFRB
48leukemia10.5
49hepatic angiomyolipoma10.5ACTC1, KIT, VIM
50prostate leiomyosarcoma10.5ANO1, CD34, KIT, PDGFRA, SDHD

Graphical network of the top 20 diseases related to Gastrointestinal Stromal Tumor:



Diseases related to gastrointestinal stromal tumor

Symptoms for Gastrointestinal Stromal Tumor

About this section

Symptoms by clinical synopsis from OMIM:

606764

Clinical features from OMIM:

606764

Symptoms:

 51 (show all 18)
  • estomach/gastric neoplasm/tumor/carcinoma/cancer
  • sarcoma
  • feeding disorder/dysphagia/swallowing/sucking disorder/esophageal dyskinesia
  • nausea/vomiting/regurgitation/merycism/hyperemesis
  • constipation
  • gastrointestinal bleeding/hemorrhage/hematemesis/melena/rectorrhagia
  • intestinal obstruction/ileus
  • intestinal perforation
  • asthenia/fatigue/weakness
  • cutaneous rash
  • irregular/in bands/reticular skin hyperpigmentation
  • hepatitis/icterus/cholestasis
  • anaemia
  • digestive neoplasm/tumor/carcinoma/cancer
  • esophageal neoplasm/tumor/carcinoma/cancer
  • small bowel neoplasm/tumor/carcinoma/cancer
  • colon neoplasm/tumor/carcinoma/cancer
  • rectum/rectal neoplasm/tumor/carcinoma/cancer

HPO human phenotypes related to Gastrointestinal Stromal Tumor:

(show all 23)
id Description Frequency HPO Source Accession
1 sarcoma hallmark (90%) HP:0100242
2 neoplasm of the stomach hallmark (90%) HP:0006753
3 feeding difficulties in infancy typical (50%) HP:0008872
4 intestinal obstruction typical (50%) HP:0005214
5 gastrointestinal hemorrhage typical (50%) HP:0002239
6 constipation typical (50%) HP:0002019
7 nausea and vomiting typical (50%) HP:0002017
8 neoplasm of the small intestine occasional (7.5%) HP:0100833
9 esophageal neoplasm occasional (7.5%) HP:0100751
10 neoplasm of the rectum occasional (7.5%) HP:0100743
11 neoplasm of the colon occasional (7.5%) HP:0100273
12 irregular hyperpigmentation occasional (7.5%) HP:0007400
13 anemia occasional (7.5%) HP:0001903
14 abnormality of the liver occasional (7.5%) HP:0001392
15 skin rash occasional (7.5%) HP:0000988
16 gastrointestinal stroma tumor HP:0100723
17 intestinal obstruction HP:0005214
18 constipation HP:0002019
19 dysphagia HP:0002015
20 large hands HP:0001176
21 neurofibromas HP:0001067
22 urticaria HP:0001025
23 hyperpigmentation of the skin HP:0000953

Drugs & Therapeutics for Gastrointestinal Stromal Tumor

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Gleevec15 41 IMATINIB MESYLATE Novartis May 2001
FDA Label: Gleevec
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:15 Gleevec™ (imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:13 1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:15 
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
2
Stivarga15 41 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
FDA Label: Stivarga
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:15 Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:13 1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:15 
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
3
Sutent15 41 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:15 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:13 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:15 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
4
Votrient15 41 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:15 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:13 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:15 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Gastrointestinal Stromal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 180)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
EverolimusapprovedPhase 4, Phase 1, Phase 21797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
3
Midazolamapproved, illicitPhase 4, Phase 163559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
4
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
5
Oxaliplatinapproved, investigationalPhase 4, Phase 1132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
6
Caffeineapproved, NutraceuticalPhase 433958-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert
Alert-Pep
Alert-pep
Allertness Aid
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
Awake
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine
Caffeine (USP)
Caffeine (natural)
Caffeine Citrate
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine citrate
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffine
Cafipel
Caféine
Circle K Nosnooze
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
Conrx Alert
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Diurex Ultra
Diurex WaterCaps
DivK1c_000730
Drowz Away Maximum strength
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Equaline Stay Awake
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Good Neighbor Pharmacy Stay Awake
Good Sense Stay Awake
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Health Mart Stay Awake
Healthy Accents Stay Awake
Hycomine
Hycomine Compound
I14-4386
IDI1_000730
 
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Leader Alertness Aid
Lil Drug Store Nosnooze
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Caffeine
Maximum Strength Snapback Stimulant Powders
Maximum Strength Stay Awake
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Nano Ppc
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Pep-back Peak Performance
Pep-back Ultra
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Smart Sense Stay Awake
Sohmed Alertness Aid
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stay Alert Aid
Stay Awake
Stay Awake Maximum Strength
Stay Awake Maximum strength
Stim
Sunmark Stay Awake
Synalgos-Dc
TNP00310
Teina
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Topcare Stay Awake maximum strength
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
7Imatinib MesylatePhase 4, Phase 3, Phase 2, Phase 1577123596
8Hypnotics and SedativesPhase 42032
9Neurotransmitter AgentsPhase 4, Phase 314795
10Psychotropic DrugsPhase 45501
11GABA ModulatorsPhase 4657
12Tranquilizing AgentsPhase 43597
13Liver ExtractsPhase 4, Phase 3, Phase 1, Phase 23572
14Pharmaceutical SolutionsPhase 4, Phase 37004
15Central Nervous System DepressantsPhase 4, Phase 310016
16AnestheticsPhase 4, Phase 3, Phase 1, Phase 27385
17Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 13162
18Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 13611
19
Erlotinib HydrochloridePhase 4, Phase 1781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
20Anesthetics, GeneralPhase 4, Phase 32274
21Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 13688
22Anesthetics, IntravenousPhase 4, Phase 31943
23Anti-Anxiety AgentsPhase 41529
24ColaNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11768
25
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
26
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
27
Dasatinibapproved, investigationalPhase 3, Phase 2, Phase 1268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
28
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
29
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
30NarcoticsPhase 32709
31AntibodiesPhase 3, Phase 2, Phase 14477
32Peripheral Nervous System AgentsPhase 3, Phase 218510
33Analgesics, OpioidPhase 32304
34Gastrointestinal AgentsPhase 3, Phase 26401
35Calcium, DietaryPhase 3, Phase 14678
36pancreatic polypeptidePhase 3, Phase 120
37Endothelial Growth FactorsPhase 3, Phase 2328
38ImmunoglobulinsPhase 3, Phase 2, Phase 14477
39Immunoglobulin GPhase 3146
40Immunologic FactorsPhase 3, Phase 1, Phase 218483
41MitogensPhase 3, Phase 21386
42AnalgesicsPhase 39358
43
LactitolPhase 2, Phase 3320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
44Antibodies, MonoclonalPhase 3, Phase 2, Phase 12413
45Histamine AntagonistsPhase 3826
46Histamine H1 AntagonistsPhase 3688
47
SerotoninPhase 3314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
48
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
49AntipruriticsPhase 3619
50Serotonin AgentsPhase 32668

Interventional clinical trials:

(show top 50)    (show all 256)
idNameStatusNCT IDPhase
1Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Phase 4
2Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 4
3Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
4Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
5Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
6Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsRecruitingNCT00777504Phase 4
7Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerRecruitingNCT00274885Phase 4
8Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibActive, not recruitingNCT00756509Phase 4
9Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study TerminationNo longer availableNCT01613053Phase 4
10Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
11Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
12Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal TumorsCompletedNCT00293124Phase 3
13Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorCompletedNCT00324987Phase 3
14Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
15Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3
16A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)CompletedNCT00075218Phase 3
17Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2, Phase 3
18Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and SunitinibCompletedNCT00471328Phase 3
19Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01462994Phase 3
20A Study of Nilotinib Versus Imatinib in GIST PatientsCompletedNCT00785785Phase 3
21Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs MaintenanceCompletedNCT00367861Phase 3
22Rechallenge of Imatinib in GIST Having no Effective TreatmentCompletedNCT01151852Phase 3
23Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
24Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
25Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative ColitisCompletedNCT00033943Phase 2, Phase 3
26A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical TreatmentRecruitingNCT00812240Phase 3
27Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)RecruitingNCT02260505Phase 3
28A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibRecruitingNCT01694277Phase 3
29Caphosol in Oral Mucositis Due to Targeted TherapyRecruitingNCT01265810Phase 3
30Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTRecruitingNCT02413736Phase 3
31Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorActive, not recruitingNCT00685828Phase 3
32Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorActive, not recruitingNCT00103168Phase 3
33Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)Active, not recruitingNCT01271712Phase 3
34Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade IndexNot yet recruitingNCT02576080Phase 3
35Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceNot yet recruitingNCT02009423Phase 3
36A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerNot yet recruitingNCT02773524Phase 3
37Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard TherapyNo longer availableNCT01646593Phase 3
38Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib MesylateTerminatedNCT00956072Phase 3
39Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
40Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsTerminatedNCT00372567Phase 3
41Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 MgTerminatedNCT00751036Phase 3
42Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) PatientsTerminatedNCT01031628Phase 3
43Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
44Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
45The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).CompletedNCT00385203Phase 2
46Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT01110668Phase 2
47S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal TumorsCompletedNCT00005597Phase 2
48Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT01267695Phase 2
49Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT00112632Phase 2
50Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal TumorsCompletedNCT01275222Phase 1, Phase 2

Search NIH Clinical Center for Gastrointestinal Stromal Tumor


Cochrane evidence based reviews: gastrointestinal stromal tumors

Genetic Tests for Gastrointestinal Stromal Tumor

About this section

Genetic tests related to Gastrointestinal Stromal Tumor:

id Genetic test Affiliating Genes
1 Gastrointestinal Stromal Tumor22 PDGFRA, KIT, SDHB, SDHC

Anatomical Context for Gastrointestinal Stromal Tumor

About this section

MalaCards organs/tissues related to Gastrointestinal Stromal Tumor:

33
Endothelial, Small intestine, Colon, Liver, Lung, Myeloid, Smooth muscle

Animal Models for Gastrointestinal Stromal Tumor or affiliated genes

About this section

MGI Mouse Phenotypes related to Gastrointestinal Stromal Tumor:

38 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000200610.0CD34, FLT3, KIT, KITLG, PDGFRA, PRKCQ
2MP:00053819.8ABL1, KIT, KITLG, MYH11, PDGFRA, PDGFRB
3MP:00053799.6ABL1, FLT3, HSP90AA1, KIT, KITLG, PDGFRA
4MP:00028739.6ABL1, ACTC1, ETV1, KIT, NTRK3, PDGFRA
5MP:00053889.4ABL1, ANO1, KIT, MYH11, NTRK3, PDGFRA
6MP:00053869.3ABL1, ANO1, ETV1, HSP90AA1, KIT, NTRK3
7MP:00036319.2ABL1, ANO1, ETV1, KIT, KITLG, NTRK3
8MP:00053879.1ABL1, CD34, FLT3, HSP90AA1, KIT, KITLG
9MP:00053699.0ABL1, ACTC1, ANO1, ETV1, KIT, MYH11
10MP:00053858.7ABL1, ACTC1, ANO1, KIT, KITLG, MYH11
11MP:00053788.6ABL1, ACTC1, ANO1, ETV1, FLT3, KIT
12MP:00053848.4ABL1, ACTC1, CD34, ETV1, FLT3, HSP90AA1
13MP:00053768.4ABL1, ACTC1, ANO1, CD34, FLT3, KIT
14MP:00107688.0ABL1, ACTC1, ANO1, ETV1, FLT3, HSP90AA1

Publications for Gastrointestinal Stromal Tumor

About this section

Articles related to Gastrointestinal Stromal Tumor:

(show top 50)    (show all 1223)
idTitleAuthorsYear
1
SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. (26291284)
2015
2
Acute porphyria precipitated by efavirenz. (25909830)
2015
3
"Apocrine Hidrocystoma and Cystadenoma"-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. (26523544)
2015
4
Interleukin-8: A critical chemokine in biliary atresia. (25611432)
2015
5
Examination of structural changes in the transforming growth factor I^ receptor 1 (TGFI^R1) gene in patients with chronic heart failure]. (25715477)
2014
6
In vivo imaging of coin-shaped lesions in cytomegalovirus corneal endotheliitis by anterior segment optical coherence tomography. (25285587)
2014
7
Heart Mitochondrial Proteome Study Elucidates Changes in Cardiac Energy Metabolism and Antioxidant PRDX3 in Human Dilated Cardiomyopathy. (25397948)
2014
8
Methylenetetrahydrofolate reductase C667T polymorphism is associated with increased risk of coronary artery disease in a Chinese population. (25124382)
2014
9
Is a policy of watch and wait after a complete response following neoadjuvant treatment for locally advanced rectal adenocarcinoma justified? Should we reset the limit? (24288010)
2013
10
Evaluation of an education intervention to implement a capability model of dementia care. (24339075)
2013
11
Immunohistochemical characterization of polyclonal antibodies against Enteromyxum leei and Enteromyxum scophthalmi (Myxozoa: Myxosporea), intestinal parasites of fish. (23957839)
2013
12
Expression profile and functional activity of peptide transporters in prostate cancer cells. (22950754)
2013
13
Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics. (23423470)
2012
14
MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. (22613005)
2012
15
Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. (21289125)
2011
16
MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. (21931765)
2011
17
Teaching NeuroImages: Schizencephaly in fetal alcohol syndrome. (22025464)
2011
18
The quality of patient-orientated Internet information on oral lichen planus: a pilot study. (20586847)
2010
19
Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. (20018852)
2010
20
Cholesterol-dependent anaplasma phagocytophilum exploits the low-density lipoprotein uptake pathway. (19283084)
2009
21
Where are we with probucol: a new life for an old drug? (19457483)
2009
22
Uterine NK cell development, migration and function. (18284874)
2008
23
Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. (18336260)
2008
24
CENP-B controls centromere formation depending on the chromatin context. (18160038)
2007
25
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. (16986126)
2006
26
Subclinical acquired syphilis masquerading as membranous glomerulonephritis. (17243528)
2006
27
hhLIM is involved in cardiomyogenesis of embryonic stem cells. (16487072)
2006
28
Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells. (16481292)
2006
29
Detection of human beta defensin-1 and -2 by RT-competitive multiplex PCR. (15821924)
2005
30
Cloning, characterization and expression of CDK5RAP1_v3 and CDK5RAP1_v4, two novel splice variants of human CDK5RAP1. (15329498)
2004
31
Somatosensory input to the ventrolateral thalamic region in the macaque monkey: potential substrate for parkinsonian tremor. (12483689)
2003
32
Structure and function of the von Willebrand factor A1 domain. (12188898)
2002
33
Large, complex, benign cystic teratoma in an adolescent. (12002202)
2002
34
Acute reversible renal failure in acute generalized exanthematous pustulosis. (12271006)
2002
35
A requirement for CARMA1 in TCR-induced NF-kappa B activation. (12154356)
2002
36
Immunogenicity of erythropoietin and other growth factors. (12735210)
2002
37
A new gene family including DSCR1 (Down syndrome candidate region 1) and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2). (10756093)
2000
38
An adolescent case of sulfhemoglobinemia associated with high-dose metoclopramide and N-acetylcysteine. (10499955)
1999
39
Cellular adhesion molecules changes in myocardium during first year post heart transplant. (9869849)
1997
40
Luteoma of pregnancy: masculinisation of a female fetus prevented by placental aromatisation. (1335753)
1992
41
Genes, variant genes and pseudogenes of the human tRNA(Val) gene family. Expression and pre-tRNA maturation in vitro. (2585499)
1989
42
Hyperbiliverdinemia in the bronze baby syndrome. (3819048)
1987
43
Eccrine sweat glands are not innervated in hereditary sensory neuropathy type IV. An electron-microscopic study. (6167137)
1981
44
Light and electron microscopic investigation of parathyroid carcinoma during dedifferentiation. Survey and study of a case. (7445424)
1980
45
Subacute combined degeneration of the spinal cord with cystinuria. (1237110)
1975
46
Surgery of endolymphatic hydrops. (4539090)
1972
47
48
49
50

Variations for Gastrointestinal Stromal Tumor

About this section

UniProtKB/Swiss-Prot genetic disease variations for Gastrointestinal Stromal Tumor:

67
id Symbol AA change Variation ID SNP ID
1KITp.Lys550IleVAR_033123rs28933968
2KITp.Val559AlaVAR_033126
3KITp.Val559AspVAR_033127
4PDGFRAp.Tyr849CysVAR_066474

Clinvar genetic disease variations for Gastrointestinal Stromal Tumor:

5 (show all 17)
id Gene Variation Type Significance SNP ID Assembly Location
1SDHBNM_003000.2(SDHB): c.725G> A (p.Arg242His)single nucleotide variantPathogenicrs74315368GRCh37Chr 1, 17349143: 17349143
2PDGFRANM_006206.4(PDGFRA): c.2525A> T (p.Asp842Val)single nucleotide variantPathogenicrs121908585GRCh37Chr 4, 55152093: 55152093
3PDGFRANM_006206.4(PDGFRA): c.2526_2537delCATCATGCATGA (p.Ile843_Asp846del)deletionPathogenicrs587776792GRCh38Chr 4, 54285927: 54285938
4PDGFRANM_006206.4(PDGFRA): c.2533_2544delCATGATTCGAAC (p.His845_Asn848del)deletionPathogenicrs587776793GRCh37Chr 4, 55152101: 55152112
5PDGFRANM_006206.4(PDGFRA): c.1682T> A (p.Val561Asp)single nucleotide variantPathogenicrs121908586GRCh37Chr 4, 55141036: 55141036
6PDGFRANM_006206.4(PDGFRA): c.1681_1682insAGAGGG (p.Arg560_Val561insGluArg)insertionPathogenicrs587776794GRCh38Chr 4, 54274868: 54274869
7PDGFRANM_006206.4(PDGFRA): c.1679_1693delGGGTCATTGAATCAA (p.Arg560_Ser564del)deletionPathogenicrs587776795GRCh38Chr 4, 54274866: 54274880
8PDGFRANM_006206.4(PDGFRA): c.1696_1713del18 (p.Ser566_Glu571del)deletionPathogenicrs121913271GRCh38Chr 4, 54274883: 54274900
9KITNM_000222.2(KIT): c.1676_1681delTTGTTG (p.Val559_Val560del)deletionPathogenicrs587776803GRCh38Chr 4, 54727444: 54727449
10KITNM_000222.2(KIT): c.1652_1666delCCATGTATGAAGTAC (p.Pro551_Val555del)deletionPathogenicrs587776804GRCh37Chr 4, 55593586: 55593600
11KITKIT, 15-BP DEL/LYS550ILEdeletionPathogenic
12KITNM_000222.2(KIT): c.1676T> A (p.Val559Asp)single nucleotide variantPathogenicrs121913517GRCh37Chr 4, 55593610: 55593610
13KITNM_000222.2(KIT): c.1648_1674del27 (p.Lys550_Lys558del)deletionPathogenicrs121913234GRCh38Chr 4, 54727416: 54727442
14KITNM_000222.2(KIT): c.1669_1674delTGGAAG (p.Trp557_Lys558del)deletionLikely pathogenicrs869025568GRCh38Chr 4, 54727437: 54727442
15SDHBNM_003000.2(SDHB): c.575G> C (p.Cys192Ser)single nucleotide variantLikely pathogenicrs397516835GRCh37Chr 1, 17350535: 17350535
16SDHDNM_003002.3(SDHD): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenicrs34677591GRCh37Chr 11, 111957665: 111957665
17SDHCNM_003001.3(SDHC): c.405+1G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs587776653GRCh37Chr 1, 161326631: 161326631

Cosmic variations for Gastrointestinal Stromal Tumor:

7 (show top 50)    (show all 1923)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
2COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
3COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
4COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
5COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
6COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
7COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
8COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
9COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
10COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
11COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
12COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
13COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
14COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
15COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
16COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
17COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
18COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
19COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
20COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
21COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
22COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
23COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
24COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
25COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
26COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
27COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
28COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
29COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
30COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
31COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
32COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
33COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
34COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
35COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
36COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
37COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
38COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
39COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
40COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
41COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
42COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
43COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
44COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
45COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
46COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
47COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
48COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
49COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3
50COSM131596MED12soft tissue,smooth muscle,leiomyoma,NS3

Expression for genes affiliated with Gastrointestinal Stromal Tumor

About this section
Search GEO for disease gene expression data for Gastrointestinal Stromal Tumor.

Pathways for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Pathways related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 25)
idSuper pathwaysScoreTop Affiliating Genes
110.1ACTC1, KIT, PDGFRA
210.0CD34, KIT, KITLG
310.0CD34, FLT3, KIT
410.0CD34, FLT3, KIT
5
Show member pathways
10.0SDHA, SDHB, SDHC, SDHD
6
Show member pathways
10.0SDHA, SDHB, SDHC, SDHD
7
Show member pathways
10.0SDHA, SDHB, SDHC, SDHD
8
Show member pathways
10.0KIT, KITLG, PDGFRA, PDGFRB
99.9CD34, FLT3, KIT, KITLG
109.9CD34, FLT3, KIT, KITLG
11
Show member pathways
9.9CD34, FLT3, KIT, KITLG
12
Show member pathways
9.9NTRK3, PDGFRA, PDGFRB, PRKCQ
139.9NTRK3, PDGFRA, PDGFRB, PRKCQ
149.8FLT3, KIT, NTRK3, PDGFRA, PDGFRB
159.8HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
16
Show member pathways
9.8ABL1, KIT, KITLG, PDGFRA, PDGFRB
17
Show member pathways
9.6FLT3, KIT, MYH11, NTRK3, PDGFRA, PDGFRB
18
Show member pathways
9.6KIT, KITLG, NTRK3, PDGFRA, PDGFRB, PRKCQ
19
Show member pathways
9.6KIT, KITLG, NTRK3, PDGFRA, PDGFRB, PRKCQ
20
Show member pathways
9.4FLT3, KIT, KITLG, NTRK3, PDGFRA, PDGFRB
219.4ABL1, FLT3, HSP90AA1, KIT, KITLG, PDGFRA
22
Show member pathways
9.4KIT, KITLG, MYH11, NTRK3, PDGFRA, PDGFRB
23
Show member pathways
9.2ABL1, HSP90AA1, KIT, KITLG, MYH11, PDGFRA
24
Show member pathways
9.1ETV1, FLT3, HSP90AA1, KIT, KITLG, NTRK3
25
Show member pathways
9.1FLT3, HSP90AA1, KIT, KITLG, NTRK3, PDGFRA

GO Terms for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Biological processes related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1succinate metabolic processGO:000610510.9SDHA, SDHB
2myeloid progenitor cell differentiationGO:000231810.9FLT3, KIT
3retina vasculature development in camera-type eyeGO:006129810.8PDGFRA, PDGFRB
4platelet-derived growth factor receptor-beta signaling pathwayGO:003579110.7ABL1, PDGFRB
5positive regulation of phospholipase C activityGO:001086310.7KIT, PDGFRA, PDGFRB
6muscle filament slidingGO:003004910.6ACTC1, VIM
7positive regulation of MAP kinase activityGO:004340610.6KIT, KITLG, PDGFRB
8regulation of phosphatidylinositol 3-kinase signalingGO:001406610.6KITLG, PDGFRA, PDGFRB
9platelet-derived growth factor receptor signaling pathwayGO:004800810.6ABL1, PDGFRA, PDGFRB
10phosphatidylinositol-mediated signalingGO:004801510.5KIT, KITLG, PDGFRA, PDGFRB
11transmembrane receptor protein tyrosine kinase signaling pathwayGO:000716910.4FLT3, KIT, PDGFRA, PDGFRB
12positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.4FLT3, KIT, PDGFRA, PDGFRB
13fibroblast growth factor receptor signaling pathwayGO:000854310.4KIT, KITLG, PDGFRA, PDGFRB
14positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.4FLT3, KIT, PDGFRA, PDGFRB
15peptidyl-tyrosine phosphorylationGO:001810810.3ABL1, HSP90AA1, NTRK3, PDGFRB
16activation of MAPKK activityGO:000018610.2KIT, KITLG, PDGFRA, PDGFRB
17cell chemotaxisGO:006032610.2KIT, PDGFRA, PDGFRB, PRKCQ
18insulin receptor signaling pathwayGO:000828610.2KIT, KITLG, PDGFRA, PDGFRB
19vascular endothelial growth factor receptor signaling pathwayGO:004801010.2HSP90AA1, KIT, KITLG, PDGFRA
20protein autophosphorylationGO:004677710.1ABL1, FLT3, KIT, NTRK3, PDGFRA, PDGFRB
21axon guidanceGO:00074119.5ABL1, KIT, MYH11, PDGFRB, PRKCQ
22innate immune responseGO:00450879.4ABL1, HSP90AA1, KIT, KITLG, PDGFRA, PDGFRB
23protein phosphorylationGO:00064689.2ABL1, FLT3, NTRK3, PDGFRA, PDGFRB, PRKCQ

Molecular functions related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1succinate dehydrogenase (ubiquinone) activityGO:000817710.7SDHA, SDHB
2oxidoreductase activity, acting on the CH-CH group of donorsGO:001662710.4SDHA, SDHC
3platelet-derived growth factor bindingGO:004840710.3PDGFRA, PDGFRB
4vascular endothelial growth factor bindingGO:003808510.3PDGFRA, PDGFRB
5protein tyrosine kinase activityGO:00047139.4ABL1, FLT3, HSP90AA1, KIT, NTRK3, PDGFRA

Sources for Gastrointestinal Stromal Tumor

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet